8-K: Tempus AI to Acquire Ambry Genetics for $375 Million Plus Stock

Tempus AI has agreed to acquire Ambry Genetics from REALM IDx, Inc. for $375 million in cash and 4,843,136 shares of Tempus AI Class A common stock.

Summary

• Tempus AI has entered into a definitive agreement to acquire Ambry Genetics from REALM IDx, Inc., a subsidiary of Konica Minolta, Inc.
• The acquisition consideration includes $375 million in cash, subject to adjustments for cash, debt, expenses, and working capital, plus 4,843,136 shares of Tempus AI Class A common stock.
• 2,152,505 of the shares will be subject to a one-year lock-up agreement.
• An additional $5 million of the cash consideration will be held in escrow for post-closing adjustments.
• Tempus AI has secured a $100 million revolving credit facility and $200 million in term loans from Ares Capital Corporation to fund the acquisition.
• The acquisition is expected to close in the first quarter of 2025, pending regulatory approvals and other customary closing conditions.
• The agreement includes termination rights for both parties, with a potential extension of up to three months if regulatory approvals are delayed.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook due to the strategic acquisition and secured financing, but there are inherent risks and uncertainties associated with the deal, leading to a moderate positive sentiment.

Positives

• The acquisition of Ambry Genetics will expand Tempus AI's capabilities in genetic testing.
• The debt financing secured by Tempus AI demonstrates confidence from lenders in the acquisition.
• The lock-up agreement on a portion of the stock consideration aligns the interests of the seller with the long-term success of Tempus AI.
• The escrow account provides a mechanism for addressing post-closing adjustments to the purchase price.

Negatives

• The acquisition is subject to regulatory approvals, which could potentially delay or prevent the deal from closing.
• The cash consideration is subject to adjustments, which could impact the final purchase price.
• A portion of the stock consideration is subject to a one-year lock-up, which may limit the seller's ability to liquidate their position.

Risks

• The acquisition is subject to regulatory approvals, which could delay or prevent the deal from closing.
• The final cash consideration is subject to adjustments based on cash, debt, expenses, and working capital of Ambry Genetics.
• There is a risk that the expected benefits of the acquisition may not be fully realized.
• The integration of Ambry Genetics into Tempus AI could present operational challenges.

Future Outlook

The acquisition is expected to close in the first quarter of 2025, subject to regulatory approvals and other customary closing conditions. The company expects to utilize borrowings under the Additional Term Loan and the Revolving Credit Facility to fund the Cash Consideration for the Acquisition and to pay fees and expenses related thereto.

Industry Context

This acquisition reflects a trend of consolidation in the genetic testing and healthcare technology sectors, as companies seek to expand their capabilities and market reach.

Comparison to Industry Standards

• The acquisition of Ambry Genetics by Tempus AI is a significant transaction in the genetic testing industry, comparable to other recent acquisitions in the healthcare technology space.
• The deal structure, involving a mix of cash and stock, is a common approach in mergers and acquisitions of this size.
• The debt financing secured by Tempus AI is typical for acquisitions of this scale, with lenders providing capital based on the perceived value and potential synergies of the combined entity.
• The regulatory approval process is a standard hurdle for acquisitions in the healthcare sector, and the timeline for closing is consistent with similar transactions.
• Comparable companies in the genetic testing space include Myriad Genetics, Invitae, and Exact Sciences, which have also engaged in acquisitions to expand their market presence and technology portfolios.

Stakeholder Impact

• Shareholders of Tempus AI will see a dilution of their ownership due to the issuance of new shares.
• Employees of Ambry Genetics will become part of Tempus AI.
• Customers of both companies may experience changes in service offerings.
• Suppliers of both companies may see changes in their business relationships.

Next Steps

• Obtain regulatory approvals for the acquisition.
• Finalize the debt financing arrangements.
• Complete the closing of the acquisition in the first quarter of 2025.
• Integrate Ambry Genetics into Tempus AI's operations.

Key Dates

Keywords

acquisition, Tempus AI, Ambry Genetics, genetic testing, merger, debt financing, stock consideration, regulatory approvals, Konica Minolta, REALM IDx